Today's health news spans regulatory approvals for cancer treatments, immigration policy impacts on physicians, safety recalls, and pandemic preparedness warnings, alongside advances in AI diagnostics and asthma research.

Capivasertib receives FDA approval for metastatic prostate cancer treatment, demonstrating a 19% improvement in radiographic progression-free survival in the CAPItello-281 trial, offering new therapeutic options for advanced disease patients.

Long-term PSA screening data suggests modest reductions in prostate cancer mortality, though experts caution about overdiagnosis risks and stress the importance of informed decision-making regarding routine screening.

AI-integrated OCT imaging system reduces unnecessary diabetic macular edema referrals in diabetic retinopathy screening, improving efficiency and reducing healthcare burden while maintaining diagnostic accuracy.

Nara Organics issues nationwide infant formula recall following FDA and CDC identification of potential botulism cases, prompting immediate action to protect vulnerable infant populations from bacterial contamination risks.

UK Health Security Agency warns of over 25% likelihood of a new pandemic within five years, citing influenza and novel coronaviruses as top threats among 22 identified risks including drug-resistant infections.

Immigrant physicians and medical students face uncertain futures as rapid federal immigration policy changes and travel bans create legal and professional barriers to entering or remaining in the United States healthcare system.

Patients with eosinophilic asthma on benralizumab therapy experience asthma attacks driven primarily by infections rather than eosinophilic inflammation, featuring airway neutrophilia, respiratory viruses, and microbiome alterations.

Cancer symptoms in ovarian, breast, and other malignancies are frequently misattributed to depression, highlighting the critical need for clinicians to distinguish between depression-driven symptoms and actual cancer-related manifestations for appropriate treatment.